Annexon Biosciences to Present at the 2022 Jefferies Healthcare Conference - Annexon Biosciences
	
	
	
	
	
	
	
	
	
	
	
	
	
	
















		
		

 



	

		

			

				
			

		

		                
                

                    

                        

        									

                        								

							

							
clinical pipeline

							
for diseases of the  body, brain & eye

						

        									

                        

											
												

													
													

														
Ben Barres, MD, PhD

														
CO-FOUNDER, ANNEXON, FORMER CHAIR OF NEUROBIOLOGY, STANFORD UNIVERSITY

														
Dr. Barres co-founded Annexon Biosciences and was a Professor and Chair of Neurobiology at Stanford University School of Medicine. He received his BS from Massachusetts Institute of Technology, his MD from Dartmouth Medical School and his PhD at Harvard Medical School in the laboratory of David Corey. Dr. Barres completed his internship and residency in neurology at the Cornell Cooperating Hospitals Program and his postdoctoral fellowship with Martin Raff at University College London. Dr. Barres won many teaching awards at Stanford and was the creator and director of the Masters of Science in Medicine Program, a program at Stanford University designed to train PhD students in human biology and disease. He was a founding member of the Myelin Repair Foundation that focuses on translational research to develop new drugs for multiple sclerosis. Dr. Barres was a Fellow of the American Academy of Arts and Sciences, the National Academy of Sciences and the Institute of Medicine. His laboratory research focused on the role of neuron-glial interactions in the central nervous system.

													

												

											
                    

                

            
    
   

            
            
Annexon Biosciences to Present at the 2022 Jefferies Healthcare Conference


            June 02, 2022


            
BRISBANE, Calif., June  02, 2022  (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that Douglas Love, Esq., president and chief executive officer, will present at the 2022 Jefferies Healthcare Conference on Thursday, June 9, 2022 at 10:30 a.m. ET in New York City.


A live webcast of the event can be accessed under the ‘Events & Presentations’ section on the Investors page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days following the presentation.


About Annexon
Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company that aims to bring game-changing medicines to patients with classical complement-mediated diseases of the body, brain and eye. The classical complement cascade is a seminal pathway within the immune system that anchors and drives a host of autoimmune, neurodegenerative and ophthalmic diseases. Annexon is advancing a new class of complement medicines targeting the early classical cascade and all downstream pathway components that contribute to disease, while selectively preserving the beneficial immune functions of other complement pathways. Annexon is rigorously developing a pipeline of diversified product candidates across multiple mid- to late- stage clinical trials, with clinical data anticipated throughout 2022 and 2023. For more information, visit www.annexonbio.com.


Contact:


Chelcie Lister
THRUST Strategic Communications
chelcie@thrustsc.com




            

« back to news page    

    





	

		

			

				

					

						
Contact Us

						

							info@annexonbio.com

							650.822.5500
						

					

					

						
Annexon, Inc.

						
1400 Sierra Point Parkway, Building C, 
2nd Floor

						Brisbane, CA 94005

					

					

							
							
					

				

				

                    
					
© 2024 Annexon, Inc.  All rights reserved.